Advanced Catheter Therapies, Inc. (ACT) is an early stage research and development medical device company with a portfolio of innovative catheter technologies targeting vascular disease including thrombosis, inflammation, occlusions and restenosis.

ACT has initially focused its resources on the problem of restenosis and is developing the game-changing Occlusion Perfusion Catheter™ (OPC™). The OPC is a multi‐lumen balloon catheter designed to temporarily occlude a specific region from blood flow to allow the local delivery of therapeutic agents to the peripheral and coronary vasculature.

Also in the development pipeline are devices to improve endovascular debulking procedures (the clearing of blocked blood vessels).

CHATTANOOGA, TN, December 18, 2012 – Advanced Catheter Therapies, Inc. (ACT) has announced the members of its Scientific Advisory Board, who will advise and assist the company in the development of current and future pipeline products.

“We are incredibly honored to have been able to attract people of this caliber to serve in an advisory capacity,” said Paul J. Fitzpatrick, CEO of ACT. “Bringing together these thought leaders will have a profound impact on ACT’s ability to develop catheter-based medical devices that improve endovascular procedures. We look forward to their guidance and experience to help accelerate our innovative devices so they can begin to benefit prospective patients as soon as possible.”